Abstract | BACKGROUND: OBJECTIVE: As novel treatment approaches for AD emerge, we characterize AD treatment and examine trends in treatment over time. METHODS: RESULTS: There were 990,000 annual visits for AD from 2003-2012 (3.2 visits/1000 people/year). TCS were the most frequently used medication (59% of visits). Topical calcineurin inhibitors (TCI) were the second most prescribed medication for AD among dermatologists (23% of visits), while antihistamines were second among all other physicians (16-44% of visits). Unlike other medications, use of TCIs decreased over time. LIMITATIONS: The NAMCS does not follow individual patients over time. CONCLUSIONS: TCI use has been decreasing. New topical AD treatments may provide an alternative to TCS, better treatment outcomes for moderate-to-severe atopic dermatitis, and an alternative to systemic antihistamines whose efficacy in AD is unproven and whose general use in AD management is discouraged by the American Academy of Dermatology. J Drugs Dermatol. 2018;17(2):135-140.
|
Authors | Alice He, Steven R Feldman, Alan B Fleischer |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
Vol. 17
Issue 2
Pg. 135-140
(Feb 01 2018)
ISSN: 1545-9616 [Print] United States |
PMID | 29462220
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Adrenal Cortex Hormones
- Anti-Bacterial Agents
- Dermatologic Agents
- Immunosuppressive Agents
|
Topics |
- Administration, Topical
- Adolescent
- Adrenal Cortex Hormones
(administration & dosage)
- Adult
- Aged
- Ambulatory Care
(trends)
- Anti-Bacterial Agents
(administration & dosage)
- Dermatitis, Atopic
(diagnosis, drug therapy, epidemiology)
- Dermatologic Agents
(administration & dosage)
- Disease Management
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage)
- Male
- Middle Aged
- Surveys and Questionnaires
- Young Adult
|